Active Not RecruitingNCT07220460
ABBV-932 for depressive episodes in people with bipolarity type I or II
About this title
Read the official source — NCT07220460Researchers are studying ABBV-932, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are studying ABBV-932, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Participants take oral capsules of ABBV-932, an investigational medication, for 26 weeks, followed by 30 days of safety follow-up. The protocol includes medical assessments, blood tests and questionnaires.
- Listed locations
- Phoenix and 48 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 30, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 84
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07220460
- Official title
Show the full official title
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Anaheim, United States · Colton, United States
42 more locations
- Garden Grove, United States
- Imperial, United States
- Lemon Grove, United States
- Long Beach, United States
- Los Angeles, United States
- Oceanside, United States
- Temecula, United States
- Walnut Creek, United States
- Cromwell, United States
- Jacksonville, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- Miami Lakes, United States
- Orlando, United States
- West Palm Beach, United States
- Atlanta, United States
- Elgin, United States
- Shreveport, United States
- Baltimore, United States
- Springfield, United States
- Jackson, United States
- St Louis, United States
- Lincoln, United States
- Las Vegas, United States
- Toms River, United States
- Brooklyn, United States
- Cedarhurst, United States
- New York, United States
- Charlotte, United States
- Avon Lake, United States
- Columbus, United States
- Oklahoma City, United States
- Portland, United States
- Allentown, United States
- Dallas, United States
- DeSoto, United States
- Richmond, United States
- The Woodlands, United States
- Bellevue, United States
- Everett, United States
- San Juan, Puerto Rico
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying ABBV-932, tracking side effects to assess long-term safety and tolerability in people with bipolarity type I or II.
What will I need to do?
You will take study medication.
Who is behind this study?
The study sponsor is AbbVie.
Does this study involve medication?
Yes. The study involves medication, including ABBV-932.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
